Related Experiment Video
Updated: Apr 20, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Acyltransferase inhibitors: a patent review (2010-present)
Taichi Ohshiro1, Hiroshi Tomoda
1Kitasato University, Graduate School of Pharmaceutical Sciences , 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641 , Japan.
Introduction:
Acyltransferase (AT) catalyzes the transfer of an acyl moiety from acyl-coenzyme A (acyl-CoA) to an acceptor. ATs play important roles in the maintenance of homeostasis in the human body and have been linked to various diseases; therefore, several ATs have been proposed as potential targets for the treatment or prevention of such diseases. The AT family includes acyl-CoA:cholesterol AT (ACAT), diacylglycerol AT (DGAT), and monoacylglycerol AT (MGAT) for the metabolism of lipids. Furthermore, recent molecular biological studies revealed the existence of their isozymes with distinct functions in the body.
Areas Covered:
This review summarized patent filings published between 2010 and the present date that claimed isozyme-selective inhibitors of ACAT, DGAT and MGAT, which are involved in neutral lipid metabolism.
Expert Opinion:
Isozymes of ACAT, DGAT and MGAT play distinct functions in neutral lipid metabolism in the human body and have been considered as potential therapeutic targets. Accordingly, isozyme-selective inhibitors that could be used in the treatment or prevention of lipid metabolism disorders were searched for. Of these, pyripyropene A derivatives, ACAT2-selective inhibitors, may be potential therapeutics for the treatment of atherosclerosis, homozygous familial hypercholesterolemia and nonalcoholic fatty liver disease.
Related Concept Videos
FDA Approved Drugs: Changes to Approved Drugs
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Drug Products: Biologics, Biosimilars and Interchangeables
Inhibitors of Viral Protein Synthesis
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

